Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains

International Journal of Antimicrobial Agents

Volumn 25, Issue 2, 2005, Pages 110-119

  File, Thomas M ^a   Garau, Javier ^b   Jacobs, Michael R ^c   Wynne, Brian ^d   Twynholm, Monique ^e   Berkowitz, Elchonon ^d  

^a SUMMA HEALTH SYSTEM   (United States)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d GLAXOSMITHKLINE   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Amoxicillin clavulanate; Community acquired pneumonia; Penicillin resistant Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DESIGN; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG SYNTHESIS; DRUG TOLERABILITY; ERADICATION THERAPY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NAUSEA; PENICILLIN RESISTANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PENICILLIN RESISTANCE; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 12344338889     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.10.007     Document Type: Article

References (22)

1. J.G. Bartlett, and L.M. Mundy Community-acquired pneumonia N Engl J Med 333 1995 1618 1624
2. M.J. Fine, M.A. Smith, and C.A. Carson Prognosis and outcomes of patients with community-acquired pneumonia A meta-analysis JAMA 275 1996 134 141
3. J. Huff, A. White, and E. Power 10-year trends in penicillin- and erythromycin-resistant Streptococcus pneumoniae for 5 European countries and the USA: the Alexander Project Abstracts from the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, USA 2002 108 [abstract C102-1624]
4. J. Garau, L. Aguilar, and M. Rodriguez-Creixems Influence of comorbidity and severity on pneumonia treated with beta-lactam monotherapy J Chemother 11 1999 266 272
5. S. Ewig, M. Ruiz, and A. Torres Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae Am J Respir Crit Care Med 159 1999 1835 1842
6. D.R. Feikin, A. Schuchat, and M. Kolczak Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance 1995-1997 Am J Public Health 90 2000 223 229
7. T.M. File Jr. Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant S. pneumoniae Clin Infect Dis 34 Suppl. 1 2002 S17 S26
8. M.R. Jacobs, D. Felmingham, and P.C. Appelbaum The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents J Antimicrob Chemother 52 2003 229 246
9. W.A. Craig Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1998 1 12
10. G. Woodnutt, and V. Berry Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory infections caused by strains of Streptococcus pneumoniae Antimicrob Agents Chemother 43 1999 29 34
11. C.M. Kaye, A. Allen, and S. Perry The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate Clin Ther 23 2001 578 584
12. E. Löwdin, O. Cars, and I. Odenholt Pharmacodynamic studies in an in vitro kinetic model of a new pharmacokinetically enhanced formulation of amoxicillin against Streptococcus pneumoniae with different susceptibilities CMI 8 2002 P1089 [abstract]
13. V. Berry, C. Singley, and J. Satterfield Efficacy of a pharmacokinetically enhanced formulation of amoxicillin/clavulanate against experimental respiratory tract infection (RTI) in rats caused by Streptococcus pneumoniae (Sp) Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, USA 2001 53 [abstract B-988]
14. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 12th informational supplement. Document M100-S12, Wayne, PA, USA: NCCLS, 2002.
15. J.-H. Song Introduction: the goals of antimicrobial therapy Int J Infect Dis 7 Suppl. 1 2003 S1 S4
16. R. Dagan, K. Klugman, and W.A. Craig Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy J Antimicrob Chemother 47 2001 129 140
17. T.M. File Jr. Community-acquired pneumonia Lancet 362 2003 1991 2001
18. T.M. File Jr., and J.S. Tan International guidelines for the treatment of community-acquired pneumonia The role of the macrolides Drugs 63 2003 181 205
19. White A, Kaye CM, Poupard JA, et al. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother, in press.
20. H.C. Neu, A.P.R. Wilson, and R.N. Grüneberg Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992 J Chemother 5 1993 67 93
21. M.-P. Richard, and B. Wynne Clinical safety of pharmacokinetically enhanced amoxicillin/clavulanate compared with currently approved formulations of amoxicillin/clavulanate Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, USA 2001 25 [abstract A-952]
22. T. File, H. Lode, and H. Kurz Comparative efficacy and safety of pharmacokinetically enhanced amoxicillin/clavulanate, 2000/125 mg vs. amoxicillin/clavulanate 875/125 mg in community-acquired pneumonia (CAP) Proceedings of the 99th International Conference of the American Thoracic Society Seattle, WA, USA 2003 370 [abstract B311]